The signaling pathways activated by TMEM16A, particularly those involving the MAPK signaling pathway, suggest that pharmacological modulation of this channel may disrupt key oncogenic mechanisms, thereby opening new avenues for cancer treatment [2]. Here, ANO1 is linked to cancer.